The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Bone metastases as predictors of treatment response and rapidly progressive disease in NSCLC patients on PD-1/PD-L1 immune checkpoint inhibitors (ICI).
 
Sally CM Lau
No Relationships to Disclose
 
Lisa W Le
No Relationships to Disclose
 
Elliot Charles Smith
No Relationships to Disclose
 
Sze Wah Samuel Chan
No Relationships to Disclose
 
Malcolm Ryan
No Relationships to Disclose
 
M. Catherine Brown
No Relationships to Disclose
 
Katrina Hueniken
No Relationships to Disclose
 
Lawson Eng
No Relationships to Disclose
 
Devalben Patel
No Relationships to Disclose
 
RuiQi Chen
No Relationships to Disclose
 
Mike Ru Sung
No Relationships to Disclose
 
Alona Zer
Consulting or Advisory Role - Boehringer Ingelheim; Lilly; MSD; Roche
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD; Roche
 
Penelope Ann Bradbury
Honoraria - Abbvie; Lilly; Merck
Consulting or Advisory Role - Abbvie; Boehringer Ingelheim
 
Pamela S Ohashi
Consulting or Advisory Role - Providence Therapeutics; Symphogen
 
Frances A. Shepherd
Stock and Other Ownership Interests - AstraZeneca; Lilly
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Serono; Merck Sharp & Dohme; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly; Merck Serono
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merrimack (Inst); Pfizer (Inst); Roche Canada (Inst)
 
Ming Sound Tsao
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck; Pfizer; Roche
Consulting or Advisory Role - Abbvie; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Celgene; Merck; Pfizer; Roche Canada
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst)
 
Geoffrey Liu
Honoraria - Abbvie; AstraZeneca; Bayer; Bristol-Myers Squibb; Merck; novartis; pfizer; Roche Canada; Takeda
Consulting or Advisory Role - AstraZeneca/MedImmune; novartis; pfizer; Roche Canada; takeda
Speakers' Bureau - AstraZeneca
Research Funding - roche (Inst)
 
Natasha B. Leighl
Research Funding - Novartis (Inst); Roche Canada (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; Nektar; Pfizer; Roche; Roche/Genentech
 
Adrian G. Sacher
Honoraria - AstraZeneca; Genentech/Roche; Merck; Pfizer
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer
Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche; Gritstone Bio; Pfizer